Aclarion's AI Platform Nociscan Receives Pinnacle Award for Innovation in Chronic Low Back Pain Diagnosis

Aclarion, Inc. has been awarded a Diamond Pinnacle Award for AI Innovation in the Clinical Decision AI category for its Nociscan solution targeting chronic low back pain. This recognition follows the company's earlier selection as a 2025 Digital Health Awards at HLTH winner, where Nociscan was honored for its potential to transform the evaluation and management of discogenic low back pain. Together, the Pinnacle and HLTH awards reflect growing external validation of Aclarion's mission to bring objective, MR spectroscopy-based biomarker analysis into routine clinical decision-making while advancing a new model of MedTech innovation built on scalable, cloud-based algorithms.

Chronic low back pain remains one of healthcare's most pervasive and costly challenges, with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Brent Ness, CEO of Aclarion, stated that receiving recognition from both the Pinnacle Awards and HLTH underscores the accelerating momentum behind their technology. Providing physicians with objective biochemical data has the potential to fundamentally improve how discogenic pain is evaluated and treated.

Aclarion's flagship platform, Nociscan, uses MR spectroscopy to identify chemical biomarkers within intervertebral discs. These biomarkers are processed through proprietary algorithms that classify whether a disc's biochemical profile is consistent with a painful or non-painful disc. Physicians use this information alongside imaging, clinical evaluation, and their own expertise to optimize treatment planning for patients with discogenic low back pain. Clinical data demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated.

The company continues to expand adoption of Nociscan among spine specialists seeking more objective tools for evaluating chronic low back pain. Since Nociscan is delivered through a cloud-based analytics platform, it can be rapidly deployed across imaging centers and health systems without requiring new hardware infrastructure. Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. For more information on Nociscan, visit https://www.aclarion.com. The latest news and updates relating to Aclarion are available at https://tinyurl.com/aconnewsroom.